India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials

 

  • Four drug candidates in the pipeline
  • Potential sales of Alzheimer’s drugs run to billions
  • Hyalolex heading for clinical trials

India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease.

Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has been found. However, the FDA has approved five medications to treat its symptoms. IGC is hoping to make Hyalolex the sixth. The drug works through a molecular pathway that allows low doses of THC to bind to Aβ plaques and so prevent them from aggregating on neurons. IGC has entered into a definitive license agreement…

Read More >>

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply